These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 589594)

  • 61. VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia.
    Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Risso M; Vimercati R; Cerri R; Rossi E
    Haematologica; 1984; 69(6):747-51. PubMed ID: 6441752
    [No Abstract]   [Full Text] [Related]  

  • 62. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
    DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
    J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).
    Canal P; Bugat R; Chatelut E; Pinel MC; Houin G; Plusquellec Y; Carton M
    Eur J Cancer Clin Oncol; 1989 May; 25(5):815-20. PubMed ID: 2737218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
    Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
    Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
    [No Abstract]   [Full Text] [Related]  

  • 65. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
    Bork E; Hansen M; Dombernowsky P; Hansen SW; Pedersen AG; Hansen HH
    J Clin Oncol; 1986 Apr; 4(4):524-7. PubMed ID: 3007684
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Given FT; Stehman FB
    Am J Clin Oncol; 1990 Apr; 13(2):117-8. PubMed ID: 2316480
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II study of VM 26 in extensively pretreated breast cancer.
    Tirelli U; Franchin G; Crivellari D; Veronesi A; Galligioni E; Trovó MG; Talamini R; Tumolo S; Grigoletto E
    Am J Clin Oncol; 1984 Oct; 7(5):451-2. PubMed ID: 6507365
    [TBL] [Abstract][Full Text] [Related]  

  • 68. VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
    Oishi N; Fleming TR; Laufman L; Ungerleider JS; Natale RB; Einstein AB; Von Hoff DD; Macdonald JS
    Invest New Drugs; 1990 Feb; 8(1):93-5. PubMed ID: 2188930
    [TBL] [Abstract][Full Text] [Related]  

  • 69. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia.
    Rivera GK; Evans WE
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):51-8. PubMed ID: 1411639
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hypersensitivity reactions to teniposide in children.
    Carstensen H; Nolte H; Hertz H; Jensen T
    J Clin Oncol; 1987 Sep; 5(9):1491-2. PubMed ID: 3625264
    [No Abstract]   [Full Text] [Related]  

  • 72. Recruitment-chemoradiotherapy with VM 26 (epipodophyllotoxin) for induction treatment of malignant brain tumours.
    Yamamoto H; Shitara N; Takakura K; Sano K
    Acta Neurochir Suppl (Wien); 1979; 28(2):616-8. PubMed ID: 290264
    [No Abstract]   [Full Text] [Related]  

  • 73. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
    Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
    Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
    Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG
    Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pulmonary hyaline membrane disease occurring in the course of VM-26 therapy.
    Commers JR; Foley JF
    Cancer Treat Rep; 1979; 63(11-12):2093-5. PubMed ID: 526943
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Uridine enhances the chemotherapeutic action of the 4'-demethylepipodophyllotoxin-thenylidene-glucoside (VM 26)-cyclophosphamide combination on i.m. implanted Ehrlich carcinoma.
    Osswald H
    Arzneimittelforschung; 1978; 28(3):387-8. PubMed ID: 580745
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anaphylactic reactions to teniposide.
    Siddall SJ; Martin J; Nunn AJ
    Lancet; 1989 Feb; 1(8634):394. PubMed ID: 2563558
    [No Abstract]   [Full Text] [Related]  

  • 78. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study.
    Eur Urol; 1976; 2(3):138-41. PubMed ID: 70352
    [TBL] [Abstract][Full Text] [Related]  

  • 79. VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report.
    Gerosa MA; Di Stefano E; Olivi A
    Surg Neurol; 1981 Feb; 15(2):128-34. PubMed ID: 6264637
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.
    Stewart DJ; Richard MT; Hugenholtz H; Dennery J; Nundy D; Prior J; Montpetit V; Hopkins HS
    J Neurooncol; 1984; 2(4):315-24. PubMed ID: 6530619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.